MBOT

Microbot Medical Inc. (MBOT) | Rumor.io

Microbot Medical

MBOT

Attention (50-day avg)0%

Attention rank (50-day avg)#2,186

Bullish sentiment (50-day avg)73%

Price to earnings ratio-4.31

Market capitalization83.9M

Earnings per share-0.25

Dividend yield (TTM)—

Revenue (annual)0

Net income (annual)-13.1M

Social

What share of all stock conversation is about MBOT?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% +0	0% +0	0% 0	0% -0.01

Aug 14

Microbot Medical Inc. ($MBOT) is trading below September 2024 support levels, with a potential drop to around $0.96/share if it fails to bounce back.
The company's secrecy and lack of business insight have led to investor frustration, with some speculating that this may be the reason for its declining stock price.
Microbot's progress towards telesurgery and development of haptic feedback is being closely watched, with some investors seeking more clarity on the company's strategy and target physician experience.

Generated by AI

Sentiment

Of the messages about MBOT that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	0% -100	41.67% -33.33	70.27% -10.76	95.59% +5.14
Bearish	100% new	58.33% +33.33	29.73% +10.76	4.41% -5.14

Bullish· May 14

Microbot Medical Inc. has seen an increase in adoption accounts, which is expected to lead to higher revenue in the coming quarters.
The company's full commercialization and partnership with Stryker Medical are major positives, indicating a strong future for the company.
Despite a recent sell-off, the market is expected to rebound as the company's technology is considered too good to be undervalued, with institutional ownership also on the rise.

Bearish· May 15

The short-selling report by White Diamond Research may have been fabricated to facilitate a short-selling attempt, potentially undermining its credibility.
The company's past lack of sales and failure to meet sales expectations may indicate underlying issues that could impact its long-term direction.
Despite a recent bearish attack, the stock price and adoption curve are showing signs of a potential substantial move north, with the stock price compressing and adoption happening more quickly than expected.

Generated by AI

Topics

Of the messages about MBOT that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	100%	100%	100%	4.25%
Technical Analysis	0%	0%	0%	1.7%
Macro	0%	0%	0%	46.12%
Analysts	0%	0%	0%	47.86%
Earnings	0%	0%	0%	0.07%
Controversies	0%	0%	0%	0.01%

Earnings· Nov 1

Microbot Medical Inc. ($MBOT) earnings are expected tomorrow, but confirmation from MGT is still pending.

Analysts· Jan 13

Microbot Medical's (MBOT) price target has been raised to $26 by H.C. Wainwright, who maintains a Buy rating on the stock.
Analysts are confident in MBOT, with a 100% buy percentage consensus, indicating a strong sentiment towards the stock.
MBOT shares have traded higher following the analyst upgrade, with a 9% increase in price.

Announcements· Jun 16

Microbot Medical Inc. (MBOT) has entered into an agreement with Lovell Government Services to expand access to its LIBERTY endovascular robotic system at over 2,000 federal healthcare facilities, including VA, DoD, and IHS sites.
The agreement is expected to enable Microbot Medical to sell its LIBERTY system at more than 2,000 government facilities, including those administered by the Veterans Health Administration, the Military Health System, and the U.S. Indian Health Service.
The federal supply schedule activation for Microbot Medical's LIBERTY system is targeted for Q3 2026, which could provide significant opportunities for the company in the federal healthcare procurement market.

Technical Analysis· Sep 8

$MBOT needs a downtrend break to shift its technical narrative from bearish to neutral/constructive.
A decisive break above the prevailing downtrend resistance is necessary to negate the current negative momentum.
A flush-and-reset pattern is possible below $4.3, requiring volume and solid tape structure to avoid a pullback.

Generated by AI

Community

Of the messages about MBOT, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	0%	81.25%	75.71%	29.27%
Newcomers	100%	18.75%	24.29%	70.73%

Regulars· Aug 14

Microbot Medical Inc. (MBOT) has dropped below its September 2024 support levels, and if it doesn't bounce back, it may get decimated to around $0.96/share.
The company's mysterious nature and lack of transparency are concerning investors, and some are questioning the effectiveness of its product, LIBERTY, in the market.
The lack of significant new news and unclear progress on development, particularly on the telesurgery front, is causing investors to lose confidence in the company, with some suggesting that the secrecy and lack of business insight are to blame.

Newcomers· Jun 28

Many newcomers are warning about potential pump attempts for MBOT, citing concerns about data accuracy and significant short interest.
Some users are skeptical about the high short interest percentage for MBOT, pointing out that it can be easily debunked by a simple Google search.
New investors are considering MBOT as a potential investment opportunity, with some believing it could be a "winner" and others questioning its legitimacy compared to WEN.

Generated by AI

News

Microbot Medical More Than Doubled Sales In Q2 Following LIBERTY Surgical Robot Launch – And It’s Expandi

14d agoBenzinga

H.C. Wainwright reiterates Microbot Medical stock rating on revenue growth

1mo agoInvesting.com

Microbot Medical earnings beat, revenue fell short of estimates

1mo agoInvesting.com

Microbot Medical Inc. (MBOT) Reports Q2 Loss, Lags Revenue Estimates

Microbot Medical (MBOT) delivered earnings and revenue surprises of 0.00% and -22.26%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

1mo agoYahoo Finance

Microbot Medical revenue more than doubles in second quarter

1mo agoInvesting.com

Microbot Medical® Files 10-Q, Reports Significant Revenue and Customer Growth During the 2026 Second Quarter

Revenue increased by more than 100% over the prior fiscal quarter, driven by repeat orders, expanded utilization among existing customers, and the acquisition of new customers since the Full Market Release in mid-April The Company added new customers in Q3 while expanding into new states and sites of service HINGHAM, Mass., Aug. 11, 2026 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT), developer and distributor of the innovative LIBERTY® Endovascular Robotic System, announced that it ha

1mo agoYahoo Finance

Also Discussed

Investors talking about MBOT also mention

#	Name	Attention
1	YTEN - Yield10 Bioscience, Inc.	——
2	Bio-Path Holdings Inc.BPTH	0%0
3	vTv Therapeutics Inc. Class A Common StockVTVT	0%new
4	Ekso Bionics Holdings, Inc.EKSO	0%new
5	Pulmatrix Inc.PULM	0%0
6	Arcadia Biosciences Inc.RKDA	0.01%0
7	AB Corporate Bond ETFEYEG	0%0
8	Nanoviricides Inc.NNVC	0%0
9	MRIN - Marin Software Incorporated	——
10	Stryker CorporationSYK	0.01%+0.01

Microbot Medical Inc.

Healthcare
Medical Instruments & Supplies

Microbot Medical Inc. is a medical device company focused on robotic technologies for minimally invasive procedures. Its current product portfolio centers on the LIBERTY Endovascular Robotic System, a disposable robotic platform designed to support catheter-based interventions in cardiovascular, peripheral, endovascular, and neurovascular care. The company also works on robotic endoluminal surgery devices aimed at improving precision and control in complex vascular pathways. Microbot Medical Inc. operates in the healthcare technology and medical devices market, where its systems are intended to help clinicians perform procedures with greater remote control and workflow efficiency. Headquartered in Hingham, Massachusetts, the company concentrates on developing specialized tools for interventional medicine and robotic-assisted procedure delivery.

Website

Location

175 Derby Street

Hingham, MA, 02043

United States

Social

What share of all stock conversation is about MBOT?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% +0	0% +0	0% 0	0% -0.01

Aug 14

Microbot Medical Inc. ($MBOT) is trading below September 2024 support levels, with a potential drop to around $0.96/share if it fails to bounce back.
The company's secrecy and lack of business insight have led to investor frustration, with some speculating that this may be the reason for its declining stock price.
Microbot's progress towards telesurgery and development of haptic feedback is being closely watched, with some investors seeking more clarity on the company's strategy and target physician experience.

Generated by AI

Sentiment

Of the messages about MBOT that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	0% -100	41.67% -33.33	70.27% -10.76	95.59% +5.14
Bearish	100% new	58.33% +33.33	29.73% +10.76	4.41% -5.14

Bullish· May 14

Microbot Medical Inc. has seen an increase in adoption accounts, which is expected to lead to higher revenue in the coming quarters.
The company's full commercialization and partnership with Stryker Medical are major positives, indicating a strong future for the company.
Despite a recent sell-off, the market is expected to rebound as the company's technology is considered too good to be undervalued, with institutional ownership also on the rise.

Bearish· May 15

The short-selling report by White Diamond Research may have been fabricated to facilitate a short-selling attempt, potentially undermining its credibility.
The company's past lack of sales and failure to meet sales expectations may indicate underlying issues that could impact its long-term direction.
Despite a recent bearish attack, the stock price and adoption curve are showing signs of a potential substantial move north, with the stock price compressing and adoption happening more quickly than expected.

Generated by AI

Topics

Of the messages about MBOT that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	100%	100%	100%	4.25%
Technical Analysis	0%	0%	0%	1.7%
Macro	0%	0%	0%	46.12%
Analysts	0%	0%	0%	47.86%
Earnings	0%	0%	0%	0.07%
Controversies	0%	0%	0%	0.01%

Earnings· Nov 1

Microbot Medical Inc. ($MBOT) earnings are expected tomorrow, but confirmation from MGT is still pending.

Analysts· Jan 13

Microbot Medical's (MBOT) price target has been raised to $26 by H.C. Wainwright, who maintains a Buy rating on the stock.
Analysts are confident in MBOT, with a 100% buy percentage consensus, indicating a strong sentiment towards the stock.
MBOT shares have traded higher following the analyst upgrade, with a 9% increase in price.

Announcements· Jun 16

Microbot Medical Inc. (MBOT) has entered into an agreement with Lovell Government Services to expand access to its LIBERTY endovascular robotic system at over 2,000 federal healthcare facilities, including VA, DoD, and IHS sites.
The agreement is expected to enable Microbot Medical to sell its LIBERTY system at more than 2,000 government facilities, including those administered by the Veterans Health Administration, the Military Health System, and the U.S. Indian Health Service.
The federal supply schedule activation for Microbot Medical's LIBERTY system is targeted for Q3 2026, which could provide significant opportunities for the company in the federal healthcare procurement market.

Technical Analysis· Sep 8

$MBOT needs a downtrend break to shift its technical narrative from bearish to neutral/constructive.
A decisive break above the prevailing downtrend resistance is necessary to negate the current negative momentum.
A flush-and-reset pattern is possible below $4.3, requiring volume and solid tape structure to avoid a pullback.

Generated by AI

Community

Of the messages about MBOT, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	0%	81.25%	75.71%	29.27%
Newcomers	100%	18.75%	24.29%	70.73%

Regulars· Aug 14

Microbot Medical Inc. (MBOT) has dropped below its September 2024 support levels, and if it doesn't bounce back, it may get decimated to around $0.96/share.
The company's mysterious nature and lack of transparency are concerning investors, and some are questioning the effectiveness of its product, LIBERTY, in the market.
The lack of significant new news and unclear progress on development, particularly on the telesurgery front, is causing investors to lose confidence in the company, with some suggesting that the secrecy and lack of business insight are to blame.

Newcomers· Jun 28

Many newcomers are warning about potential pump attempts for MBOT, citing concerns about data accuracy and significant short interest.
Some users are skeptical about the high short interest percentage for MBOT, pointing out that it can be easily debunked by a simple Google search.
New investors are considering MBOT as a potential investment opportunity, with some believing it could be a "winner" and others questioning its legitimacy compared to WEN.

Generated by AI

Microbot Medical

Social

Aug 14

Bullish· May 14

Bearish· May 15

Earnings· Nov 1

Analysts· Jan 13

Announcements· Jun 16

Technical Analysis· Sep 8

Regulars· Aug 14

Newcomers· Jun 28

Microbot Medical More Than Doubled Sales In Q2 Following LIBERTY Surgical Robot Launch – And It’s Expandi

H.C. Wainwright reiterates Microbot Medical stock rating on revenue growth

Microbot Medical earnings beat, revenue fell short of estimates

Microbot Medical Inc. (MBOT) Reports Q2 Loss, Lags Revenue Estimates

Microbot Medical revenue more than doubles in second quarter

Microbot Medical® Files 10-Q, Reports Significant Revenue and Customer Growth During the 2026 Second Quarter

Also Discussed

Microbot Medical Inc.

Company Information

Location

Microbot Medical More Than Doubled Sales In Q2 Following LIBERTY Surgical Robot Launch – And It’s Expandi

H.C. Wainwright reiterates Microbot Medical stock rating on revenue growth

Microbot Medical earnings beat, revenue fell short of estimates

Microbot Medical Inc. (MBOT) Reports Q2 Loss, Lags Revenue Estimates

Microbot Medical revenue more than doubles in second quarter

Microbot Medical® Files 10-Q, Reports Significant Revenue and Customer Growth During the 2026 Second Quarter

Also Discussed

Social

Aug 14

Bullish· May 14

Bearish· May 15

Earnings· Nov 1

Analysts· Jan 13

Announcements· Jun 16

Technical Analysis· Sep 8

Regulars· Aug 14

Newcomers· Jun 28